PubMed Health⌕ Search

Biomedical subjects

Jie Yu

Publications and source records attributed to Jie Yu.

3 recordsLinked to original sources
PubMed2026

Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

AIMS: This study aims to systematically evaluate the efficacy of bimagrumab on body composition and glucose parameters in adults with obesity and metabolic dysfunction and its safety profile. METHODS: We searched MEDLINE, PubMed, Embase, and the Cochrane Library on April 20, 2026, for randomized controlled trials (RCTs) assessing bimagrumab treatment in adults with obesity, insulin resistance, or type 2 diabetes mellitus (T2DM). The risk of bias was assessed using the Cochrane Risk of Bias tool (RoB 2), and meta-analyses of efficacy and safety data were conducted using R software. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system was used to assess the strength of evidence. The study was registered with PROSPERO (CRD420261377110). RESULTS: Of the 134 retrieved records, 4 RCTs (enrolling 268 participants) were included. The included population represented a broad spectrum of metabolic dysfunction, from obesity and nondiabetic insulin resistance to established T2DM. Compared with placebo, bimagrumab treatment significantly reduced total weight (mean difference [MD] -4.85 kg, 95% confidence interval [CI] -6.82 to -2.88), fat mass (-4.72 kg [-8.05 to -1.40]), and glycated haemoglobin (HbA1c) (-0.13% [-0.23 to -0.03]) and significantly increased total lean mass (1.66 kg [0.81 to 2.51]). However, bimagrumab led to an increase in low-density lipoprotein (LDL) concentrations of 0.47 mmol/L [0.03 to 0.91] and significantly increased incidences of discontinuation (risk ratio [RR] 5.75 [1.61 to 20.46]), muscle spasms (RR 10.44 [4.23 to 25.75]), and diarrhoea (RR 4.91 [2.38 to 10.11]). CONCLUSION: Bimagrumab effectively reversed adverse effects on body composition in obese individuals, resulting in significant fat reduction, increased skeletal muscle mass, and improved glycemic control, suggesting that bimagrumab is a promising new target for personalized metabolic therapy.

Humans↗
PubMed2025

Reversing the paradigm: Oxygen-dependent switch of nTiO₂ from promoting to suppressing ARG conjugation.

The environmental spread of antibiotic resistance genes (ARGs) poses a significant public health threat. While nano-titanium dioxide (nTiO2) is known to promote ARG transfer, its role in prevalent anaerobic environments remains poorly understood. Therefore, we comprehensively evaluated the influence of nTiO2 exposure on the plasmid-mediated ARGs conjugation under aerobic/anaerobic conditions. Under aerobic conditions, nTiO2 significantly promoted the ARGs dissemination through both intra-genus (E. coli to E. coli) and inter-genus (E. coli to P. denitrificans) transfer. Reactive oxygen species (ROS) was determined as the decisive factor driving aerobic conjugation, which increased membrane permeability and downregulated conjugative pathways. Addition of ROS scavenger thiourea effectively abolished the stimulatory effect of nTiO₂ on conjugative transfer. However, nTiO2 treatment significantly inhibited conjugative ARG transfer under anaerobic conditions. The dose-dependent inhibition was confirmed in anaerobic denitrification system. Exogenous H2O2 switched the inhibitory effect of nTiO₂ on anaerobic conjugation. Physical barrier formed by nTiO₂ adsorption might contribute to inhibited conjugative transfer of ARGs. Therefore, this study defines the distinct roles of the inhibitory physical effect caused by the adsorption barrier and promotive chemical effect induced by ROS in the nTiO₂-mediated ARG conjugation, which contributes to a deeper understanding of the environmental propagation mechanisms of ARGs under nanomaterial exposure.

Reactive Oxygen Species↗
PubMed2024

A novel variant in the SPTB gene underlying hereditary spherocytosis and a literature review of previous variants.

BACKGROUND: Hereditary spherocytosis (HS, MIM#612641) is one of the most common hereditary hemolytic disorders. This study aimed to confirm a novel variant's pathogenicity and reveal a patient's genetic etiology. METHODS: The clinical data of a patient with HS who underwent genetic sequencing at the Children's Hospital of Chongqing Medical University were reviewed retrospectively. In silico prediction and in vitro minigene splicing reporter system were then conducted on the detected variant to analyze its intramolecular impact. A summary of the literature related to HS due to SPTB gene variants was also presented. RESULTS: A novel variant (c.301-2 A > G) in the SPTB gene (NM_001024858.4) was identified in the proband. Using Sanger sequencing, we conclusively confirmed that the inheritance of the variant could not be traced to the biological parents. The in vitro minigene assay revealed three different transcripts derived from the c.301-2 A > G variant: r.301_474del, r.301_306delCCAAAG, and r.301-1_301-57ins. Through a literature review, patients with HS who had been genotypically validated were summarized and the SPTB gene variant profile was mapped. CONCLUSION: We identified a splicing variant of the SPTB gene, thus confirming its aberrant translation. The novel variant was the probable genetic etiology of the proband with HS. Our findings expanded the variant spectrum of the SPTB gene, thus improving the understanding of the associated hereditary hemolytic disorders from a clinical and molecular perspective and contributing to the foundation of genetic counseling and diagnosis.

Humans↗